SVB Securities analyst Mani Foroohar downgraded Decibel Therapeutics to Market Perform from Outperform with a price target of $2, down from $7.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics reports Q4 cash position $104.6M vs $162.3M last year
- Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Frequency’s failure highlights Decibel’s differentiation, says H.C. Wainwright
- Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting